Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus FOLFOX4 versus panitumumab plus FOLFIRI for KRAS wild-type colorectal cancer with liver-only metastases
2008-006766-28Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Objective response rate. Started Jan 2009; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-006766-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006766-28.